Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Doses of Antiretroviral Drugs to Eliminate Latent HIV-1 Reservoir
NCT06640192Phase 2Active, not recruiting
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dolutegravir, maraviroc and lamivudine in human immunodeficiency virus infection (HIV) (2 arms). Primary endpoint: Variation in the size of the latent cellular reservoir of HIV-1 at 48 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
dolutegravirmaraviroclamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06640192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640192.